

Gunderson Dettmer Advised Sales Agents on Arcus Biosciences, Inc. “At-the-Market” Offering

Client News

February 28, 2023

Gunderson Dettmer advised sales agents Goldman Sachs & Co. LLC and SVB Securities in a proposed \$200 million “at-the-market” offering of common stock for Arcus Biosciences, Inc. Public companies partner Jeffrey Vetter and corporate partner Marcia Hatch and associates Elena Vespoli, Daniel Reichert, Sherrie Quinn, Leanne Gould, and Phoebe Hung led the team advising the sales agents.

Arcus, which trades on the New York Stock Exchange under the ticker symbol “RCUS,” is a clinical-stage biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer.

Companies

[Goldman Sachs & Co. LLC](#)

[SVB Securities](#)

[Arcus Biosciences, Inc.](#)

Related People





Jeffrey R. Vetter

PARTNER

P +1 650 321 2400



Marcia A. Hatch

PARTNER

P +1 734 585 2220



Elena M. Vespoli

ASSOCIATE

P +1 646 490 9092

Related Services

Private & Public Companies

Public Companies

Featured Insights

CLIENT NEWS

Brazilian Carbon Capture Company Mombak Announces \$30M Financing

CLIENT NEWS

Africa B2B OmniRetail Announces \$20M Financing

CLIENT NEWS

Glacier Announces Series A Financing to Expand Robot Recycling Fleet

CLIENT NEWS

Dataminr Announces \$100M Investment Led by Fortress Investment Group

CLIENT NEWS

Omnidian Announces \$87M Series C for Renewable Energy Performance

INSIGHTS

Splitting the Pie: How Savvy Founders Divide Ownership and Navigate Other Founder Equity Decisions

CLIENT NEWS

Chainguard Announces \$356 Million Series D Led by Kleiner Perkins and IVP

INSIGHTS

Client Insight: California AI Transparency Act

INSIGHTS

Client Insight: Prepare for BE-10 Benchmark Survey of US Direct Investment Abroad

INSIGHTS

Tech Brew Interviews Aaron Rubin in “Where the legal battle stands around copyright and AI training”

CLIENT NEWS

Latin America Fintech Belvo Announces \$15M Funding

INSIGHTS

